Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Providence Health & Services
Shanghai Junshi Bioscience Co., Ltd.
Helsinki University Central Hospital
Tianjin Medical University Cancer Institute and Hospital
National Cancer Centre, Singapore
Dana-Farber Cancer Institute
ASLAN Pharmaceuticals
UNC Lineberger Comprehensive Cancer Center
Ziekenhuis Oost-Limburg
SCRI Development Innovations, LLC
Memorial Sloan Kettering Cancer Center
Northwestern University
Mayo Clinic
Roswell Park Cancer Institute